Answers are grounded in this paper and cite their sources.
Background: Recent evidence has converged to indicate that the gut microbiome is involved in neurodegeneration via immune, metabolic, and neural mechanisms, but these reports are spread across diseases, designs and levels of certainty. RQ1: What are the gut microbial signatures in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD)? and RQ2: Is there compelling evidence that the microbiome plays a causal role in disease and has therapeutic potential? The method used was purposive selection of 50 human observational studies, meta-analyses, preclinical experiments, intervention studies and reviews from peer-reviewed sources relevant to this study (2015-2024) and coding by disease and design and appraising using a five-stage evidence ladder. Results: Evidence focused on PD (40%) and AD (34%) with only moderate evidence coverage for ALS (10%) and HD (4%). A convergent functional signature was supported in PD and plausible in AD, but not in ALS or HD, and there was a significant difference in taxa between diseases. The causal evidence in animals was most convincing in the transfer, germ-free, and colonization experiments, while in humans, the causal evidence was preliminary, limited, and somewhat uncontrolled. Conclusions: H1 was somewhat supported and H2 was supported. In order to implement microbiome-based diagnostics and therapies in clinical practice, there is a need for large longitudinal metagenomic cohorts, medication adjusted designs, and sufficiently powered randomized trials.
No takes yet. Share an insight, caveat, or question.
Tarar et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: